Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Autodesk Inc (ADSK) Price & Performance

ADMA Biologics Inc
Autodesk Inc

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Autodesk Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Autodesk Inc trades at $208.7 (market cap $44.84B). The key difference: Autodesk Inc is far larger — about 21.1× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.

ADMAADSK
Market Cap
$2.13B$44.84B
Sector
HealthTechnology
52-Week High
$20.38$326.79
52-Week Low
$7.60$187.72
Enterprise Value
$2.20B$44.64B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Autodesk Inc

Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.

Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK